预约演示
更新于：2025-05-31
BAY-85-8102
更新于：2025-05-31
概要
基本信息
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H27FN4O2 |
InChIKeyFLZZFWBNYJNHMY-VNRZBHCFSA-N |
CAS号958233-09-5 |
关联
28
项与 BAY-85-8102 相关的临床试验NCT05238961
Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy
NCT04542603
Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer
NCT06453915
NeuroFLiPP - Parametric PET of Neuroinflammation in Fatty Liver Disease
100 项与 BAY-85-8102 相关的临床结果
登录后查看更多信息
100 项与 BAY-85-8102 相关的转化医学
登录后查看更多信息
100 项与 BAY-85-8102 相关的专利（医药）
登录后查看更多信息
160
项与 BAY-85-8102 相关的文献（医药）2025-06-01JOURNAL OF THE NEUROLOGICAL SCIENCES
A mini-review: Application of the radiopharmaceutical [18F]DPA-714 in neuroinflammation research in post-SARS-CoV-2 patients
Review
作者: Boniek, Douglas ; Malamut, Carlos
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has been linked to significant neurological complications, including neuroinflammation. This mini review explores the application of the radiopharmaceutical [18F]DPA-714 in neuroinflammation studies in post-SARS-CoV-2 patients using Positron Emission Tomography - Computed Tomography (PET-CT) imaging technology. [18F]DPA-714, a specific ligand for the translocator protein (TSPO), enables precise visualization and quantification of microglial activation, a key marker of neuroinflammation. Recent studies demonstrate that post-COVID-19 patients exhibit increased uptake of [18F]DPA-714 in various brain regions, correlating with persistent symptoms such as fatigue, cognitive dysfunction, and mood alterations. The application of [18F]DPA-714 in longitudinal studies can monitor the progression of neuroinflammation and evaluate the efficacy of therapeutic interventions, allowing personalized treatment adjustments. Additionally, exploring new TSPO ligands can complement data obtained with [18F]DPA-714, offering a more comprehensive view of neuroinflammatory processes. This article discusses the technical challenges in synthesizing and applying [18F]DPA-714, including the need for standardized imaging protocols and variability in binding due to genetic polymorphisms in TSPO. As a conclusion that [18F]DPA-714 is a valuable tool for research and treatment of neuroinflammation in post-SARS-CoV-2 patients, with significant implications for the development of personalized therapies and clinical monitoring.
2025-02-01CNS Neuroscience & Therapeutics
Hybrid PET /MRI Imaging of 18F ‐Fluorodeoxyglucose and 18‐kDa Translocator Protein for Presurgical Localization in Refractory Epilepsy
Article
作者: Wang, Jingjuan ; Lu, Jie ; Yao, Chenyang ; Zhang, Siqi ; Cui, Bixiao ; Hu, Jie ; Wang, Zhenming ; Qi, Zhigang
ABSTRACT:
Purpose:
Surgery remains the only curative option for a third of refractory epilepsy patients, though success depends on precise localization of the epileptogenic zone (EZ). This study aims to assess the clinical value of hybrid 18F‐FDG and 18F‐DPA‐714 PET/MRI for accurate localization and precise boundary delineation.
Methods:
The refractory epilepsy patients who underwent surgery at Xuanwu Hospital from November 2022 to November 2023 were retrospectively recruited. Preoperative simultaneous 18F‐FDG and 18F‐DPA‐714 PET/MRI imaging were analyzed using the asymmetry index (AI) and a 4‐point visual score, with the surgical site and pathological findings serving as the gold standard.
Results:
A total of 43 patients (mean age: 26.30 ± 8.37 years, male: 28) were included in this study. Lesion localization accuracy within the EZ was 76.7% for 18F‐FDG PET/MRI, 69.8% for 18F‐DPA‐714 PET/MRI, and 60.5% for conventional MRI (p = 0.26). In 26 MRI‐positive cases, conventional MRI accurately localized all lesions within the EZ, with three cases showing negative findings on 18F‐FDG images and six on 18F‐DPA‐714. Among 17 MRI‐negative patients, thirteen demonstrated positive results on hybrid PET/MRI. Additionally, 18F‐DPA‐714 PET/MRI proved more effective in delineating lesion boundaries. Compared to 18F‐FDG, the AI score was significantly lower (0.25 ± 0.18 vs. 0.46 ± 0.19, p < 0.001), while the visual score was higher (4.00 ± 2.00 vs. 3.00 ± 0.00, p = 0.01).
Conclusion:
18F‐DPA‐714 PET/MRI can effectively complement conventional MRI in the preoperative assessment of refractory epilepsy, with localization accuracy on par with 18F‐FDG and enhanced capability in delineating lesion boundaries.
2024-12-01JOURNAL OF NEUROLOGY
18F-DPA714 PET/MRI as a potential imaging tool for detecting possible antibody-negative autoimmune encephalitis: a prospective study
Article
作者: Chen, Sheng ; Zhou, Qinming ; Zhang, Yu ; Hai, Wangxi ; Zhang, Min ; Chunyu, Hangxing ; Meng, Huanyu ; Qu, Qian ; He, Lu ; Li, Biao ; Wang, Jin
BACKGROUND AND OBJECTIVES:
Conventional magnetic resonance imaging (MRI) used for detecting possible antibody-negative autoimmune encephalitis (AIE) often fails to meet the diagnostic requirements of this disease. Positron emission tomography (PET) with a translocator protein radioligand can help visualize microglia distribution density in inflammation-related diseases, thereby offering potentially incremental value to conventional MRI for the in vivo assessment of possible antibody-negative AIE.
METHODS:
In this prospective study, 15 participants diagnosed with possible antibody-negative AIE and 10 healthy controls were enrolled (ClinicalTrials.gov: NCT05293405, dated March 15, 2022). All participants underwent hybrid 18F-DPA714 PET/MRI and evaluation for modified Rankin scale (mRS) score, clinical assessment scale for AIE (CASE), and appropriate antibodies. A positive finding was defined as the intensity of 18F-DPA714 uptake that was above a threshold of mean standardized uptake value ratio (SUVR) + two standard deviations of SUVR within the corresponding brain regions of healthy controls.
RESULTS:
The positive detection rate of 18F-DPA714 PET for possible antibody-negative AIE was significantly higher than that of brain MRI (10/15 [67%] vs. 3/15 [20%]; P = 0.039). In addition, both the intensity and extent of 18F-DPA714 uptake were significantly associated with the CASE score (P = 0.002 and 0.001). Meanwhile, SUVR levels in the cerebellar region were significantly higher in patients with ataxia than in those without ataxia (P = 0.006). Furthermore, 18F-DPA714 uptake decreased in 5/10 [50%] patients who underwent follow-up PET/MRI, which mirrored their symptom relief.
CONCLUSION:
18F-DPA714 PET demonstrated its potentially incremental value to conventional MRI for detecting possible antibody-negative AIE.
100 项与 BAY-85-8102 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 神经炎症 | 临床2期 | 美国 | 2018-03-22 | |
| 帕金森病 | 临床2期 | 美国 | 2018-03-22 | |
| 颈动脉狭窄 | 临床1期 | 美国 | 2026-04-01 | |
| 卵巢上皮癌 | 临床1期 | - | 2025-06-01 | |
| 新冠肺炎后遗症 | 临床1期 | 美国 | 2023-11-10 | |
| 严重急性呼吸综合征 | 临床1期 | 美国 | 2023-11-10 | |
| 特发性肺纤维化 | 临床1期 | 美国 | 2020-12-08 | |
| 急性心肌梗塞 | 临床1期 | 美国 | 2019-10-17 | |
| 慢性疲劳综合征 | 临床1期 | 美国 | 2019-02-03 | |
| 纤维肌痛 | 临床1期 | 美国 | 2019-02-03 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | (Patients with autoimmune encephalomyelitis) | 鹽觸鏇艱餘淵範窪積構(範範獵網餘衊願壓積窪) = 齋積製壓壓膚願糧衊繭 壓齋壓獵齋獵繭製鏇遞 (範構獵鏇願築蓋廠夢醖 ) | - | 2023-08-28 | ||
(Healthy controls) | 鹽觸鏇艱餘淵範窪積構(範範獵網餘衊願壓積窪) = 鏇衊構餘繭夢衊積鏇憲 壓齋壓獵齋獵繭製鏇遞 (範構獵鏇願築蓋廠夢醖 ) | ||||||
N/A | 23 | 齋顧夢簾糧餘遞積鏇壓(膚窪膚衊製憲築蓋築憲) = 積夢憲鏇簾鹹淵積願襯 夢願獵鬱齋艱遞淵鑰鹹 (顧繭簾鏇醖衊醖鹽艱觸 ) 更多 | 积极 | 2022-09-22 | |||
N/A | - | - | (High affinity binders (HAB)) | 鹹鹽襯夢構構簾艱鬱築(網製選積夢遞範襯積鏇) = 鹽艱糧繭築鹹艱鑰襯簾 構遞繭觸窪糧齋鏇構鏇 (選顧醖遞製蓋鹽襯製齋 ) | - | 2016-05-24 | |
(Mixed affinity binders (MAB)) | 鹹鹽襯夢構構簾艱鬱築(網製選積夢遞範襯積鏇) = 窪鏇選遞鏇製築簾淵鑰 構遞繭觸窪糧齋鏇構鏇 (選顧醖遞製蓋鹽襯製齋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用